Milestone Pharmaceuticals Inc.

MIST

$1.32

+$0.00 (0.00%)

Closed

Loading chart...

IndexN/A

Market Cap0.11B

Enterprise Value0.15B

Income$-0.02B

Sales$0.00B

EmployeesN/A

P/E-1.94

P/S109.60

P/B4.06

P/C-3.43

EV/EBITDA-2.60

EV/SalesN/A

EPS (ttm)-0.68

EarningsN/A

Gross Margin92.63%

Oper. Margin-4041.72%

Profit Margin-4078.78%

Volume1.05M

Shs Outstand0.09B

ChangeN/A

Dividend Est.N/A

Dividend Ex-DateN/A

Perf YTDN/A

Perf YearN/A

Perf 3YN/A

Perf 5YN/A

Perf 10YN/A

IPON/A

Jul 209:30PMMilestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(globenewswire.com)09:30PMMilestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(globenewswire.com)

Jun 2309:00AMAlpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board(gurufocus.com)

Jun 1001:32PMMilestone Pharmaceuticals Inc. (MIST) Shareholder/Analyst Call Prepared Remarks Transcript(seekingalpha.com)

Insider Trading

View All

Insider

Type

Price

Value

Date

PAPA JOSEPH C

Award

77.0K

$1.22

$94K

Jun 10, 26

Saik Andrew

Award

77.0K

$1.22

$94K

Jun 10, 26

TOMSICEK MICHAEL JOHN

Award

77.0K

$1.22

$94K

Jun 10, 26

Wills Robert James

Award

77.0K

$1.22

$94K

Jun 10, 26

Duty Stuart

Award

77.0K

$1.22

$94K

Jun 10, 26

Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, specializing in the creation and commercialization of cardiovascular therapeutics. Their flagship product, etripamil, an innovative channel blocker, is currently in advanced clinical development. It is undergoing Phase III trials for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the United States and Canada, while also progressing through Phase II trials for atrial fibrillation and rapid ventricular rate. Furthermore, Milestone Pharmaceuticals has forged a licensing and collaboration alliance with Ji Xing Pharmaceuticals to advance and distribute etripamil for both preventative and therapeutic applications in humans. The company was founded in 2003.

CEO: Joseph G. OlivetoEmployees: 33www.milestonepharma.com

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Revenue	N/A	$1.00M	$5.00M	$15.00M	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	$10.00K	$8.00K
Gross Profit	N/A	$1.00M	$5.00M	$15.00M	N/A	N/A	$-10.00K	$-8.00K
Gross Margin	0.00%	100.00%	100.00%	100.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses	$42.10M	$62.10M	$64.64M	$58.07M	$50.71M	$57.88M	$23.81M	$8.26M
Operating Income	$-42.10M	$-61.10M	$-59.64M	$-43.07M	$-50.71M	$-57.88M	$-23.82M	$-8.27M
Operating Margin	0.00%	-6109.80%	-1192.84%	-287.15%	0.00%	0.00%	0.00%	0.00%
Net Income	$-41.52M	$-59.69M	$-58.39M	$-42.85M	$-49.97M	$-55.23M	$-23.18M	$-8.09M
Net Margin	0.00%	-5968.50%	-1167.76%	-285.69%	0.00%	0.00%	0.00%	0.00%
EPS (Basic)	$-0.67	$-1.39	$-1.35	$-1.02	$-1.70	$-3.50	$-0.98	$-0.34
EBITDA	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Stock Option Compensation Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Price To Earnings Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Price To Sales Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Shares Outstanding	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Market Capitalization	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Milestone Pharmaceuticals Inc.

Insider Trading

Discover more